Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -159.38 Million USD | 39.54% |
| 2022 | -263.62 Million USD | 7.72% |
| 2021 | -285.68 Million USD | -23.55% |
| 2020 | -231.22 Million USD | -50.14% |
| 2019 | -154.01 Million USD | 5.09% |
| 2018 | -162.26 Million USD | -57.79% |
| 2017 | -102.84 Million USD | 13.04% |
| 2016 | -118.25 Million USD | -11.76% |
| 2015 | -105.81 Million USD | -241.48% |
| 2014 | -30.98 Million USD | -17.97% |
| 2013 | -26.26 Million USD | -60.13% |
| 2012 | -16.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -20.95 Million USD | 38.55% |
| 2024 Q3 | -38.84 Million USD | -40.13% |
| 2024 Q2 | -27.72 Million USD | -32.32% |
| 2023 Q4 | -34.09 Million USD | -14.75% |
| 2023 FY | -159.38 Million USD | 39.54% |
| 2023 Q1 | -48.39 Million USD | -2.07% |
| 2023 Q2 | -47.17 Million USD | 2.51% |
| 2023 Q3 | -29.71 Million USD | 37.02% |
| 2022 FY | -263.62 Million USD | 7.72% |
| 2022 Q4 | -47.41 Million USD | 14.77% |
| 2022 Q3 | -55.62 Million USD | 36.73% |
| 2022 Q2 | -87.92 Million USD | -21.0% |
| 2022 Q1 | -72.66 Million USD | 15.51% |
| 2021 Q4 | -86 Million USD | -11.23% |
| 2021 Q3 | -77.32 Million USD | -11.83% |
| 2021 FY | -285.68 Million USD | -23.55% |
| 2021 Q1 | -53.21 Million USD | 13.23% |
| 2021 Q2 | -69.14 Million USD | -29.92% |
| 2020 Q1 | -49.08 Million USD | -17.52% |
| 2020 FY | -231.22 Million USD | -50.14% |
| 2020 Q2 | -64.87 Million USD | -32.16% |
| 2020 Q3 | -55.93 Million USD | 13.77% |
| 2020 Q4 | -61.33 Million USD | -9.65% |
| 2019 Q1 | -36.69 Million USD | 13.91% |
| 2019 Q4 | -41.76 Million USD | -14.82% |
| 2019 Q2 | -39.17 Million USD | -6.75% |
| 2019 Q3 | -36.37 Million USD | 7.14% |
| 2019 FY | -154.01 Million USD | 5.09% |
| 2018 Q4 | -42.62 Million USD | 1.77% |
| 2018 FY | -162.26 Million USD | -57.79% |
| 2018 Q3 | -43.39 Million USD | -10.78% |
| 2018 Q2 | -39.16 Million USD | -5.62% |
| 2018 Q1 | -37.08 Million USD | -13.38% |
| 2017 Q3 | -23.75 Million USD | -27.61% |
| 2017 Q2 | -18.61 Million USD | 32.92% |
| 2017 Q1 | -27.75 Million USD | 0.99% |
| 2017 FY | -102.84 Million USD | 13.04% |
| 2017 Q4 | -32.7 Million USD | -37.67% |
| 2016 Q4 | -28.03 Million USD | 7.13% |
| 2016 Q3 | -30.18 Million USD | 4.31% |
| 2016 FY | -118.25 Million USD | -11.76% |
| 2016 Q1 | -28.49 Million USD | 2.98% |
| 2016 Q2 | -31.54 Million USD | -10.69% |
| 2015 Q2 | -21.69 Million USD | 3.17% |
| 2015 FY | -105.81 Million USD | -241.48% |
| 2015 Q4 | -29.37 Million USD | 9.2% |
| 2015 Q3 | -32.34 Million USD | -49.14% |
| 2015 Q1 | -22.4 Million USD | -46.44% |
| 2014 Q4 | -15.29 Million USD | -135.21% |
| 2014 Q2 | -4.61 Million USD | -0.81% |
| 2014 Q3 | -6.5 Million USD | -41.03% |
| 2014 FY | -30.98 Million USD | -17.97% |
| 2014 Q1 | -4.57 Million USD | 43.05% |
| 2013 Q2 | -10.81 Thousand USD | 99.8% |
| 2013 Q3 | -4.78 Million USD | -44135.15% |
| 2013 Q1 | -5.4 Million USD | -458.71% |
| 2013 FY | -26.26 Million USD | -60.13% |
| 2013 Q4 | -8.03 Million USD | -67.86% |
| 2012 Q4 | -966.61 Thousand USD | 0.0% |
| 2012 FY | -16.4 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bright Green Corporation | -8.89 Million USD | -1692.534% |
| Alvotech | -354.86 Million USD | 55.086% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 439.318% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -955.364% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 195.46% |
| Cosmos Health Inc. | -21.83 Million USD | -630.06% |
| Journey Medical Corporation | -2.07 Million USD | -7588.423% |
| Dynavax Technologies Corporation | -37.02 Million USD | -330.434% |
| Embecta Corp. | 221.5 Million USD | 171.955% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -2.454% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 281.786% |
| PainReform Ltd. | -9.58 Million USD | -1562.99% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3230.638% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3230.638% |
| SCYNEXIS, Inc. | 72.66 Million USD | 319.325% |
| Safety Shot Inc | -12.18 Million USD | -1208.101% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -6236.67% |
| Alpha Teknova, Inc. | -35.56 Million USD | -348.165% |
| Procaps Group, S.A. | 38.97 Million USD | 508.952% |
| Theratechnologies Inc. | -10.62 Million USD | -1399.774% |
| Harrow Health, Inc. | 580 Thousand USD | 27579.483% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -3290.364% |
| Biofrontera Inc. | -22.67 Million USD | -602.831% |
| DURECT Corporation | -36.88 Million USD | -332.114% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2924.881% |
| Cronos Group Inc. | -81.37 Million USD | -95.859% |
| OptiNose, Inc. | -22.74 Million USD | -600.637% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 176.246% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -307.072% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 1361.724% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 1372.503% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -3575.492% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -2466.183% |
| Radius Health, Inc. | -3.92 Million USD | -3960.662% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -4419.172% |
| ProPhase Labs, Inc. | -21.61 Million USD | -637.431% |
| Phibro Animal Health Corporation | 53.31 Million USD | 398.942% |
| Procaps Group S.A. | 52.32 Million USD | 404.604% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -1770.011% |
| Viatris Inc. | 766.2 Million USD | 120.801% |
| Rockwell Medical, Inc. | -6.67 Million USD | -2289.52% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -2933.517% |
| SIGA Technologies, Inc. | 83.62 Million USD | 290.599% |
| Tilray Brands, Inc. | -174.74 Million USD | 8.792% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 1808.081% |
| Shineco, Inc. | -17.06 Million USD | -833.917% |
| PetIQ, Inc. | 60.01 Million USD | 365.569% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -3264.792% |
| Incannex Healthcare Limited | -30.04 Million USD | -430.545% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 163.524% |
| Alimera Sciences, Inc. | -1.47 Million USD | -10734.874% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2271.371% |
| Assertio Holdings, Inc. | -243.53 Million USD | 34.555% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -2604.866% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -1070.425% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -922.066% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -694.915% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | -15.62% |
| Hempacco Co., Inc. | -8.81 Million USD | -1708.624% |
| Talphera, Inc. | -16.88 Million USD | -843.697% |
| Alvotech | -354.86 Million USD | 55.086% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 398.165% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 143.709% |
| Currenc Group, Inc. | -6.64 Million USD | -2298.227% |
| Kamada Ltd. | 10.06 Million USD | 1683.674% |
| Indivior PLC | -4 Million USD | -3884.525% |
| Evoke Pharma, Inc. | -7.43 Million USD | -2044.844% |
| Flora Growth Corp. | -50.35 Million USD | -216.521% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -694.915% |
| Evolus, Inc. | -49.23 Million USD | -223.728% |
| HUTCHMED (China) Limited | 18.37 Million USD | 967.38% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 180.909% |
| Akanda Corp. | -10.05 Million USD | -1485.664% |